Holen Sie sich die Stockscreener-App
10.86
7.63%
0.77
Vorhandelsmarkt:
11.00
0.14
+1.29%
Kura Oncology Inc Aktie (KURA) Neueste Nachrichten
Kura Oncology Q3 EPS Increased by Brookline Capital Markets - MarketBeat
Q3 EPS Estimates for Kura Oncology Boosted by HC Wainwright - MarketBeat
Kura Oncology (KURA) investors report up to 9.7% beneficial ownership stakes - Stock Titan
Kura Oncology (NASDAQ:KURA) Stock Price Up 8% on Analyst Upgrade - MarketBeat
A Quick Look at Today's Ratings for Kura Oncology(KURA.US), With a Forecast Between $23 to $40 - Moomoo
Kura Oncology FY2029 EPS Cut by Brookline Capital Markets - MarketBeat
Kura Oncology (KURA) Q2 2026 Earnings Call: KOMZIFTI-Umsatz erreicht 9,1 Mio. USD - TradingKey
A Quick Look at Today's Ratings for Kura Oncology(KURA.US), With a Forecast Between $28 to $40 - moomoo.com
BofA Securities Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $31 - Moomoo
Kura Oncology, Inc. Stock 12‑Month Price Target Raised to $32, Implies 222% Upside - TradingView
Kura Oncology (NASDAQ:KURA) Shares Gap Up After Strong Earnings - MarketBeat
KURA Maintained by Wedbush -- Price Target Raised to $38 - GuruFocus
Kura Oncology (NASDAQ:KURA) Price Target Raised to $38.00 at Wedbush - MarketBeat
Wedbush Adjusts Price Target on Kura Oncology to $38 From $36, Keeps Outperform Rating - marketscreener.com
Kura Oncology (NASDAQ:KURA): What Does the Latest Update Mean for Clinical Evidence? - Kalkine Media
Kura Oncology, Inc. Stock 12‑Month Price Target Raised to $31.83, Implies 220% Upside - tradingview.com
Kura Oncology (KURA) Q2 2026 Results Highlight Valuation Challen - GuruFocus
Kura Oncology Q2 2026 Earnings Call Transcript - MarketBeat
Kura Oncology, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Kura Oncology Q2 EPS $(0.77) beats estimate, sales miss - scanx.trade
Kura Oncology Q2 Earnings Call Highlights - MarketBeat
Earnings call transcript: Kura Oncology tops Q2 2026 estimates as launch gains - Investing.com
Kura Oncology (NASDAQ:KURA) Issues Earnings Results - MarketBeat
Kura Oncology (KURA) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
Kura Oncology, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Kura Oncology Inc (KURA) Reports Q2 Revenue of $20.9M with Net L - GuruFocus
Kura Oncology Q2 Diluted Loss Widens, Revenue Rises - marketscreener.com
Kura Oncology: Q2 Earnings Snapshot - KTVB
Earnings Flash (KURA) Kura Oncology Posts Q2 Loss Per Share $0.77, vs. FactSet Est of Loss $0.88 - marketscreener.com
KURA ONCOLOGY ($KURA) Releases Q2 2026 Earnings - Quiver Quantitative
Q2 2026 Kura Oncology, Inc. Earnings Call Transcript - GuruFocus
Kura Oncology (KURA) grows revenue to $39.1M but widens net loss - Stock Titan
Kura Oncology, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Kura Oncology Q2 product revenue rises 57% on KOMZIFTI uptake - TradingView
Kura Oncology Reports Second Quarter 2026 Financial Results - The Manila Times
Earnings Flash (KURA) Kura Oncology, Inc. Reports Q2 Revenue $20.9M, vs. FactSet Est of $20.2M - marketscreener.com
BRIEF-Kura Oncology Q2 Operating Expenses USD 93.884 Million - TradingView
Kura Oncology, Inc. expected to post a loss of 88 cents a shareEarnings Preview - TradingView
Kura Oncology (KURA) Eps Diluted (TTM) - Zacks Investment Research
Kura Oncology (KURA) Advances Menin Inhibitor Research Amid Mixed Market Signals - GuruFocus
Kura Oncology highlights ziftomenib preclinical activity, menin binding profile in Blood publication - Bitget
Kura Oncology publishes preclinical data on ziftomenib in Blood By Investing.com - Investing.com South Africa
Kura Oncology publishes preclinical data on ziftomenib in Blood - Investing.com
Kura Oncology publishes study highlighting zift... - Pluang
Kura Oncology Announces Blood Publication Detailing Discovery, Preclinical Characterization and Resistance Profile of Ziftomenib - Quiver Quantitative
Kura Oncology Announces Publication in Blood Highlighting Ziftomenib’s Differentiated Binding Profile and Preclinical Activity - The Manila Times
Kura Oncology Announces Publication in Blood Highlighting - globenewswire.com
Hennion & Walsh Asset Management Inc. Grows Stake in Kura Oncology, Inc. $KURA - MarketBeat
Dimensional Fund Advisors LP Increases Holdings in Kura Oncology, Inc. $KURA - MarketBeat
Sei Investments Co. Boosts Holdings in Kura Oncology, Inc. $KURA - MarketBeat
Kura Oncology Inc (KURA) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Kura Oncology, Inc. (KURA) stock price, news, quote and history - Yahoo Finance Australia
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Kura Oncology, Inc. (KURA) Stock Analysis: Exploring a 235.85% Potential Upside in the Biotechnology Sector - DirectorsTalk Interviews
Six New Employees Receive Kura Oncology Options at $9.19 - Stock Titan
Kura Oncology to Report Second Quarter 2026 Financial Results on August 12, 2026 - Quiver Quantitative
Kura Oncology to Report Second Quarter Financial Results - The Manila Times
Cancer drugmaker Kura Oncology schedules Aug. 12 webcast - Stock Titan
How Kura Oncology Inc. (KURA) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Kura Oncology, Inc. $KURA Shares Sold by Renaissance Technologies LLC - MarketBeat
Kura Oncology, Inc. (KURA) Stock Analysis: Exploring a Potential 234% Upside in the Biotech Sector - DirectorsTalk Interviews
Kura Oncology (NASDAQ: KURA) revises CEO and executive severance - Stock Titan
KURA Reiterates by Wedbush -- Price Target Maintained at $36 - GuruFocus
Kura Oncology Inc (KURA) Institutional Confidence - TradingKey
Kura Oncology, Inc. (NASDAQ:KURA) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
KURA|Kura Oncology Inc|Price:10.150|Chg%:-0.240 - TradingKey
Kura Oncology posts investor presentation on darlifarnib plus cabozantinib clinical update in renal cell carcinoma - Bitget
H.C. Wainwright Maintains Kura Oncology(KURA.US) With Buy Rating, Maintains Target Price $40 - Moomoo
0.52%
0.07%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):